Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies.
David brings experience in business development as well as executive managerial experience in public companies, Sanofi and BiolineRx.
Jessicca is an oncology leader with many years of experience in both clinical development and medical affairs supporting the development and approval of oncology products, such as Cyramza® , Halaven®, Lenvima®, and Sprycel®.
Hagop is an experienced oncology drug developer with tenures in several pharmaceutical and biotech companies, including as Chief Medical Officer at ImClone-Lilly and as President of R&D at Ziopharm. He was involved in the development and approval of multiple oncology biologics, such as Erbitux®, Cyramza®, and Taxotere®.